Dr Virginia (Ginny) Acha has been appointed as the ABPI's new Executive Director - Research Medical and Innovation (RM&I). Dr Acha will take up the position at the beginning of March and report directly to ABPI Chief Executive Stephen Whitehead.
Dr Acha currently works for Amgen as Director, Global Regulatory and R&D Policy – Europe, Middle East and Africa. She holds the chair for the Pharmacovigilance working group in the IFPMA Bio therapeutics Committee, and is the Vice-Chair for the European Biopharmaceutical Enterprises (EBE) Biosimilars Task Force and the lead for the EFPIA Regulatory Network supporting Turkey.Previously, she spent nearly five years at Pfizer working on policy development and engagement in a number of domains, including science, innovation and access and choice in healthcare.
Dr Acha entered the pharmaceutical industry after a decade in academia where she held posts on innovation strategy at Imperial College London Business School, the Science Policy Research Unit (SPRU) at the University of Sussex, the Centre for Research in Innovation Management (CENTRIM) at the University of Brighton, as well as a post-doctoral fellowship at London Business School. She is also a Visiting Researcher in the Innovation & Entrepreneurship Department at Imperial College Business School London.
Welcoming Dr Acha’s appointment ABPI Chief Executive Stephen Whitehead said:
“I am delighted by Ginny’s appointment at what is a very important time for our industry when we need to demonstrate the very high value of the UK’s research and development capability in the pharmaceutical industry on the global stage. Ginny’s experience and background will complement that of our members’ to champion science, discovery, research and development and enable it to thrive in the UK. I am really looking forward to working with her.”
Commenting on her appointment Dr Acha said:
“These are exciting times in the science, development and delivery of medicines, and so it is a great privilege to be joining the ABPI now to help deliver our industry’s views and aspirations for the future of healthcare. I’m looking forward to engaging with all of our community in the UK and sharing our passion for science and innovation.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com